SEC and FDA sign 3-year market integrity pact

The SEC and FDA signed a three-year cooperation agreement on Aug. 31 that gives the agencies formal channels for exchanging nonpublic information about regulated products, public companies and potential legal violations.

The MOU allows the Securities and Exchange Commission to use information obtained from the Food and Drug Administration during company filing reviews, enforcement investigations, administrative proceedings and civil actions.

The agreement takes effect immediately. It does not announce an investigation, new disclosure rule or enforcement case against any company. It instead creates procedures that could help the agencies compare corporate statements with information held by the FDA.

The MOU establishes a framework for the agencies to enhance cooperation in their regulatory and enforcement responsibilities in order to improve market oversight and compliance. https://t.co/XUAf4rlo7a

— U.S. Securities and Exchange Commission (@SECGov) August 31, 2026

SEC and FDA cooperation targets conflicting disclosures

Public biotechnology, pharmaceutical, medical device and healthcare companies frequently release information about clinical trials, FDA submissions, regulatory reviews and product approvals. Those announcements can move stock prices because they affect a product’s commercial prospects.

The SEC reviews whether public companies provide complete and accurate information to investors. The FDA separately receives regulatory submissions, trial information and safety data that may not yet be public. Better coordination could help the SEC identify inconsistencies between corporate disclosures and regulatory records.

The MOU specifically mentions representations about FDA reviews, product approvals and clinical trial results. The agencies said their cooperation is “expected to bolster informed decision-making” and improve oversight, but the agreement does not guarantee more enforcement cases.

SEC Chairman Paul Atkins said FDA-related disclosures can materially affect financial markets. Acting FDA Commissioner Kyle Diamantas said faster information sharing should improve transparency across the life sciences sector while protecting patients and public trust.

Nonpublic records will receive confidentiality safeguards

Each agency will establish a mechanism for receiving information requests and transferring nonpublic material securely. Requests must describe the information sought, explain its intended use and carry authorization from the requesting office.

The SEC will appoint contacts from its Division of Enforcement and Division of Corporation Finance. The FDA will appoint contacts from its Office of the Chief Counsel and Office of Inspections and Investigations. The FDA chief counsel’s office will also lead referrals involving potential securities violations.

The MOU permits the FDA to share records that may otherwise be exempt from public disclosure, subject to federal restrictions covering trade secrets and confidential commercial information. The SEC cannot provide FDA information to an outside party without written FDA permission.

Likewise, the FDA must give confidentiality assurances before receiving nonpublic SEC records. Shared information does not become public merely because it passes between the agencies, and the exchange does not waive legal privileges.

The agreement does not cover requests for public records, subpoenas or testimony. It only applies to requests submitted after its Aug. 31 effective date.

The agreement strengthens an existing enforcement tool

The MOU does not give either regulator new statutory powers. Instead, it organizes how the agencies use their existing authority and establishes designated contacts to reduce delays when information is needed.

For the SEC, the most direct use may involve checking statements in earnings releases, securities filings or investor presentations against FDA records. If those statements appear materially false or incomplete, the information could support further questions, a filing review or an enforcement investigation.

The same disclosure principle remains relevant across the SEC’s wider jurisdiction. As crypto.news reported, the SEC’s proposed crypto offering exemptions retain antifraud liability when issuers make materially misleading statements, even if an offering does not require full registration.

Interagency information sharing also appears elsewhere in financial oversight. In related coverage, the SEC and Commodity Futures Trading Commission maintain an information-sharing arrangement covering private fund data, reducing the need for duplicate reporting while preserving regulatory access.

Both agencies can modify or end the MOU

The SEC and FDA may extend or modify the agreement through mutual written consent. Either agency may terminate it by providing 30 days’ advance notice.

Implementation remains subject to available staff, funding and other resources. The document states that it represents the agencies’ intentions and does not create legally enforceable obligations against either regulator.

The next step is operational. Both agencies must maintain designated contacts and may develop standard procedures and templates for handling nonpublic information requests. No separate implementation deadline was announced.

The MOU will expire in August 2029 unless the agencies extend it. Until then, its practical reach will depend on how frequently regulators use the new channels during filing reviews and investigations.